ECSP055588A - Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico - Google Patents

Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico

Info

Publication number
ECSP055588A
ECSP055588A EC2005005588A ECSP055588A ECSP055588A EC SP055588 A ECSP055588 A EC SP055588A EC 2005005588 A EC2005005588 A EC 2005005588A EC SP055588 A ECSP055588 A EC SP055588A EC SP055588 A ECSP055588 A EC SP055588A
Authority
EC
Ecuador
Prior art keywords
quinoxaline
methyl
fluorobencil
dihidroxi
octil
Prior art date
Application number
EC2005005588A
Other languages
English (en)
Inventor
John Charles Kath
Christopher Stanley Poss
Jane Li Zheng
Bryan Li Zhengong
Eric Brock Mcelroy
Clifford Nathaniel Meltz
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP055588A publication Critical patent/ECSP055588A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxaline-2-carboxílico, útiles en el tratamiento o prevención de un trastorno o afección por medio de la antagonización del receptor CCR1, y sus métodos de preparación y uso.
EC2005005588A 2002-08-12 2005-02-03 Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico ECSP055588A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40321602P 2002-08-12 2002-08-12

Publications (1)

Publication Number Publication Date
ECSP055588A true ECSP055588A (es) 2005-04-18

Family

ID=31715961

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005588A ECSP055588A (es) 2002-08-12 2005-02-03 Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico

Country Status (22)

Country Link
US (1) US20040072834A1 (es)
EP (1) EP1539715A1 (es)
JP (1) JP2005538130A (es)
AP (1) AP2005003226A0 (es)
AR (1) AR040839A1 (es)
AU (1) AU2003250450A1 (es)
BR (1) BR0313378A (es)
CA (1) CA2494776A1 (es)
EC (1) ECSP055588A (es)
GT (1) GT200300169A (es)
IL (1) IL166548A0 (es)
IS (1) IS7674A (es)
MX (1) MXPA05001781A (es)
NO (1) NO20050540L (es)
OA (1) OA12894A (es)
PA (1) PA8580401A1 (es)
PE (1) PE20040866A1 (es)
TN (1) TNSN05035A1 (es)
TW (1) TW200407316A (es)
UY (1) UY27928A1 (es)
WO (1) WO2004014875A1 (es)
ZA (1) ZA200500768B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201130810A (en) 2009-12-23 2011-09-16 Ironwood Pharmaceuticals Inc CRTH2 modulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN102276539B (zh) * 2011-06-29 2013-08-14 赵雪梅 一种具有抑菌作用的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
CN1248968A (zh) * 1997-02-26 2000-03-29 辉瑞大药厂 杂芳基－己酸酰胺衍生物、其制备方法及其作为MIP－1α与其CCRI受体结合的选择性抑制剂的用途
KR100385529B1 (ko) * 1998-02-05 2003-05-27 화이자 프로덕츠 인코포레이티드 신규 디하이드록시헥산산 유도체

Also Published As

Publication number Publication date
US20040072834A1 (en) 2004-04-15
AP2005003226A0 (en) 2005-03-31
AR040839A1 (es) 2005-04-20
MXPA05001781A (es) 2005-04-25
PA8580401A1 (es) 2004-02-16
IL166548A0 (en) 2006-01-15
UY27928A1 (es) 2004-03-31
OA12894A (en) 2006-10-13
NO20050540L (no) 2005-03-10
AU2003250450A1 (en) 2004-02-25
WO2004014875A1 (en) 2004-02-19
TW200407316A (en) 2004-05-16
CA2494776A1 (en) 2004-02-19
JP2005538130A (ja) 2005-12-15
PE20040866A1 (es) 2004-11-26
ZA200500768B (en) 2006-07-26
IS7674A (is) 2005-01-27
TNSN05035A1 (fr) 2007-05-14
BR0313378A (pt) 2005-07-12
EP1539715A1 (en) 2005-06-15
GT200300169A (es) 2004-05-12

Similar Documents

Publication Publication Date Title
PA8579601A1 (es) Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
WO2005102396A3 (en) Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof
ATE433978T1 (de) 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
CL2006003736A1 (es) Compuestos derivados de triazina o pirimidina sustituida, antagonistas del receptor de prokineticina 1, composicion farmaceutica; y uso en el tratamiento de trastornos gastrointestinales.
DK1373256T3 (da) CCR5-antagonister, der er nyttige til behandling af AIDS
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2007073497A3 (en) Calcium channel antagonists
WO2005123737A3 (en) Charge-transport materials, methods of fabrication thereof, and methods of use thereof
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
IS2733B (is) Afleiður af díoxan-2-alkýlkarbamötum, framleiðsluaðferð þeirra, milliefni notuð við framleiðsluna, og notkun þeirra í meðferð.
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
BRPI0514579A (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e gaboxadol, e, processo para preparo de um composto
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
DE60230722D1 (de) Il-8-rezeptor-antagonisten
CL2003001415A1 (es) Compuestos d derivados de naftil, quinolinil e isoquinolinil urea; composicion farmaceutica; y uso en el tratamiento y prevencion de condiciones de dolor y en el sibndrome del colon irritable y condiciones asociadas.
ECSP055588A (es) Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
DOP2003000682A (es) Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,3-dihidroxi-7-metil-octil]-amida del acido quinoxalina-2-carboxilico
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen